Icosavax push­es for­ward com­bo RSV-hM­PV vac­cine and an­nounces di­rect stock of­fer­ing

Seat­tle-based Icosavax may have failed in its at­tempt at a Covid-19 vac­cine in 2022, but it re­leased ear­ly da­ta on its bi­va­lent vac­cine can­di­date for RSV and hu­man metap­neu­movirus (hM­PV) — and an­nounced a $67.8 mil­lion di­rect of­fer­ing of its com­mon stock yes­ter­day.

The vac­cine can­di­date for old­er adults, dubbed IVX-A12 and grant­ed fast track des­ig­na­tion by the FDA, is made up of the com­pa­ny’s RSV and hM­PV vac­cines. The bi­va­lent vac­cine could po­ten­tial­ly take mean­ing­ful mar­ket share in a fu­ture ~$10 bil­lion+ mar­ket.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN